Brief: Satsuma Pharmaceuticals Reports Fourth Quarter Loss Per Share Of $0.49
15/03/2022 20:45
March 15 (Reuters) - Satsuma Pharmaceuticals Inc STSA.O :
* SATSUMA PHARMACEUTICALS REPORTS 2021 FULL YEAR AND FOURTH
QUARTER FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS
* SATSUMA PHARMACEUTICALS INC - $95.8 MILLION IN CASH, CASH
EQUIVALENTS AND MARKETABLE SECURITIES AS OF DECEMBER 31, 2021,
PROVIDES RUNWAY INTO H2 OF 2023
* SATSUMA PHARMACEUTICALS INC - STS101 SUMMIT PHASE 3
EFFICACY
TRIAL ENROLLMENT ONGOING; KEY TRIAL ON TRACK TO READ OUT TOPLINE
RESULTS IN Q4 2022
* SATSUMA PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.49
Source text for Eikon: ID:nGNX6jPDKT
Further company coverage: STSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Satsuma Pharmaceuticals
See all newsBrief: Satsuma Pharmaceuticals Announces FDA Acceptance Of 505(B)(2) NDA For Sts101, A Novel And Investigational Dihydroergotamine Nasal Powder Product For The Acute Treatment Of Migraine
Commencement Of Tender Offer For Satsuma Pharmaceuticals, Inc In U.S.
Brief: Satsuma Pharmaceuticals Says Received Letter Notifying Co Regained Compliance With Nasdaq
U.S. STOCKS ON THE MOVE-Alphabet Inc, BlackRock, Moderna
Satsuma Pharma soars on buyout deal from Japan's Shin Nippon